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PrognosisAbstract Aims: This prospective cross-sectional observational study aimed at reporting the
demographics of ACS patients admitted to Assiut University Hospital, Egypt, and validating both
TIMI (Thrombolysis in Myocardial Infarction) and GRACE (Global Registry of Acute Coronary
Events) scores in the prediction of both in-hospital MACE and 30-day mortality and recurrent MI
in both ST-elevation myocardial infarction (STEMI) and unstable angina/non-ST-elevation
myocardial infarction (UA/NSTEMI) patients.
Methods: Data were collected from all admitted patients over one year from April 1, 2011.
Results: The study included 795 patients, 270 (34%) with STEMI and 525 (66%) with UA/
NSTEMI with a comparable mean age (58 ± 11 vs 57 ± 12 years, respectively). The STEMI
patients had higher rates of male gender (75% vs 64%), smoking (51% vs 38%), and familial
predisposition (16% vs 7%). The UA/NSTEMI patients had higher rates of a history of previous
ischemia (70% vs 24%), hypertension (59% vs 33%), and diabetes (45% vs 34%). STEMI was asso-
ciated with a higher in-hospital MACE (23.3% vs 13.7%) and a higher 30-day all-cause mortality
rate (9% vs 2%) and recurrent non-fatal MI (35% vs 15%).
4 H.M. Abdelmoneim et al.Conclusion: ACS occurs at a relatively young age in our locality, in patients sharing common
known coronary risk factors. STEMI patients, in our locality, represent approximately one-third
of ACS patients and are associated with worse in-hospital as well as 30-day outcomes. Both TIMI
and GRACE risk scores are valid for use in ACS patients in the Assiut governorate (c-statistics
0.72–0.97), with a better discriminative ability for the GRACE score, especially in UA/STEMI
patients.
Open access under CC BY-NC-ND license.
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Patients presenting with acute coronary syndromes (ACS) with
or without ST segment elevation despite having both common
etiology and pathophysiology form a heterogeneous popula-
tion with variable short and long prognoses. Early risk strati-
ﬁcation plays an important role in deciding the optimal
management of these patients, and the concept of risk assess-
ment has become widespread in the last few years [1,2]. Risk
stratiﬁcation in ACS aims to identify patients at high risk of
death or recurrent ischemic events who might beneﬁt from fur-
ther investigations and treatment. Moreover, it can identify
low-risk patients amenable to early hospital discharge. Thus,
risk stratiﬁcation allows better cost–beneﬁt clinical resource
utilization, such as decisions regarding transfer to tertiary cen-
ters, level of care, length of hospital stay, and which pharma-
cological and interventional treatments should be used [2].
Several prognostic scores have recently been proposed.
Some are derived from clinical trials such as TIMI (Thrombol-
ysis in Myocardial Infarction) [3,4], PURSUIT (Platelet glyco-
protein IIb–IIIa in Unstable angina, Receptor Suppression
using Integrilin Therapy trial) [5], and GUSTO (Global Utili-
zation of Streptokinase and t-PA for Occluded coronary arter-
ies) [6] scores. Others are derived from registries and cohort
studies such as PREDICT (the Predicting Risk Of Death In
Cardiac Disease Tool) [7], CCP (Cooperative Cardiovascular
Project) [8] and GRACE (Global Registry of Acute Coronary
Events) [9] scores. Both TIMI and GRACE scores can be cal-
culated from initial clinical history and electrocardiographic
and laboratory data collected on admission. Both scores are
sufﬁciently simple to be practical at the bedside for risk assess-
ments across a wide spectrum of patients with ACS [1,2].
Subjective risk judgments by treating physicians have been
reported to affect the selection of more aggressive therapies
than would be chosen if patients were objectively stratiﬁed
by validated risk score models. Risk scores still confer indepen-
dent and greater prognostic information compared with physi-
cian risk assessment after adjusting for treatment differences.
Therefore, dedicated efforts to improve and implement risk
stratiﬁcation may enhance the overall care process and
resource utilization [10].
Risk stratiﬁcation scoring systems do predict outcome more
accurately in the original setting than when used for other
patient populations. This difference has been attributed to
the signiﬁcant differences with regard to the initial patient pop-
ulation on which the score design was based [11]. Several stud-
ies have assessed ACS risk stratiﬁcation scores in a number of
countries [4,9,10,12–14]. In addition, the comparative perfor-
mance of these scores in representative patient populations
has not been well studied [11]. In addition, data are lackingconcerning the demographics and clinical presentation pat-
terns of ACS in Egypt.
This study aimed to report the demographics of ACS
patients admitted to Assiut University Hospital, comparing
ST segment elevation myocardial infarction (STEMI) with
unstable angina/non-ST segment elevation myocardial infarc-
tion (UA/NSTEMI) patients. In addition, the study aimed to
validate both TIMI and GRACE scores as prognostic tools
to predict both in-hospital major acute cardiac events (MACE)
and 30-day all-cause mortality and recurrent MI in both
STEMI and UA/NSTEMI patients.2. Methods
This study was a prospective cross-sectional observational
study that included all patients >18 years old who had ACS
and were admitted to the coronary care unit in Assiut Univer-
sity Hospital over a period of one year: from the 1st of April
2011 to the 31st of March 2012. All patients provided a written
informed consent. The study was approved by our faculty
ethics committee and was adherent to the regulations of the
Declaration of Helsinki.
Ischemic type chest pain was identiﬁed as being retroster-
nal, severe, crushing, squeezing, constricting, or discomforting
with frequent radiation to the left arm or known history of
coronary artery disease, including MI [2]. Patients were
assigned to the categories of STEMI, NSTEMI, or unstable
angina, according to standard deﬁnitions [2,15].
The exclusion criteria were (1) patients with non-coronary
causes of chest pain (i.e., trauma, aortic aneurysm, pulmonary
embolism, or pericarditis), (2) patients with acute dyspnea
from non-cardiac causes, and (3) signiﬁcant co-morbidity
reducing life expectancy to <1 year as patients with advanced
liver diseases, cerebrovascular diseases, malignancy and
chronic lung diseases that could affect patient prognosis.
2.1 Data collection
Patients were managed according to the European guide-
lines for the management of ACS patients [1,16]. STEMI
patients were reperfused using streptokinase. Coronary
intervention was performed when it was ﬁnancially eligible.
The daily review of admitted cases with ACS fulﬁlling the
inclusion criteria was performed. The full history and
examination data were reported. A standard 12-lead elec-
trocardiogram (ECG) record was recorded at a paper speed
of 25 mm/s and ampliﬁcation of 10 mm/mV. Laboratory
evaluation at the baseline included random blood sugar,
serum lipid proﬁle, serum urea and creatinine, creatine
Validation of TIMI and GRACE scores in ACS patients 5kinase, troponin and hemoglobin level on admission. Daily
follow-up evaluation of serum urea, creatinine, and crea-
tine kinase throughout the admission period was also
performed.
2.2 Risk score assessment
The GRACE score was calculated as previously reported
[2,9] from the following variables and weighted according
to risk model: age, history of congestive heart failure, history
of MI, heart rate, systolic blood pressure on presentation,
ST-segment deviation, initial serum creatinine and cardiac
enzymes raised above the upper limit of normal for that
laboratory.
For STEMI, the TIMI risk score [4] is a weighted integer
score based on eight clinical risk indicators that can be easily
ascertained at presentation. For each patient, the score was
calculated as the arithmetic sum of the points of each risk fea-
ture present (range from 0 to 14).
For NSTEMI, the TIMI score [3] is based on clinical indi-
cators, each assigned one point, ranging from 0 to 7.
2.2.1. In-hospital outcomes
All of the patients were reviewed daily until hospital discharge to
record major acute cardiac events (MACE). Only the most seri-
ous events ofmajor adverse cardiac events were used to calculate
the cumulative major adverse cardiac events per patient accord-
ing to the following sequence: death > asystole > cardiogenic
shock > pulmonary edema > serious arrhythmia > recurrent
non-fatal MI > recurrent or refractory angina. MACE is
reported according to the standard deﬁnitions [2,15].
The patients were followed up for 30 days from admission
by telephone interviews after being discharged. The primary
endpoints at follow-up were all-cause mortality and recurrent
non-fatal MI [2,15].
2.3. Statistical analysis
Risk scores were calculated according to TIMI and GRACE
risk score models [3,4,9]. Data were analyzed using Statistical
Package for Social Sciences (SPSS) version 16.0. The 0.05
level was used as the cut-off value for statistical signiﬁcance.
The count and percentage were used for describing and sum-
marizing qualitative data. The arithmetic mean and standard
deviation (SD) were used as measures of central tendency
and dispersion, respectively, for quantitative data. The dif-
ferences in mortality rates for increasing TIMI and Grace
Risk scores values were assessed using the v2 test for trend.
The risk score discrimination models that distinguish well
between patients who die and those who survive are said to
have good discrimination. The discrimination of TIMI and
Grace scores were tested using Receiver Operating Charac-
teristics (ROC) curve (c-statistics). The c-index ranges from
0 to 1, with higher values indicating better discrimination.
The ROC curve was constructed using 10% stepwise incre-
ments in predicted mortality. The curve is generated by plot-
ting the true positive proportion or sensitivity (Y axis)
against the false positive proportion, which is 1-speciﬁcity
(X axis), across the range of model to produce the curve. A
model with equal probability of producing the correct orincorrect result (e.g., ﬂipping a coin) produces a straight line
at a 45 angle with is half of the area under the curve. Models
with better discrimination incorporate larger areas under the
curve to a theoretical maximum of 1.0. Comparison of ROC
curves to test the statistical signiﬁcance of the difference
between the areas under the dependent ROC curves (derived
from the same cases) was performed with the method of
DeLong et al. [17] using MedCalc Statistical software Ver-
sion 13.1.2 (Ostend, Belgium).
3. Results
3.1. Studied sample and follow-up
The total number of patients included in the study was 795.
The patients were divided into two groups: 270 patients
(34%) with STEMI and 525 patients (66%) with UA/NSTE-
MI. The number of UA patients was 330 (41.5%), and the
number of NSTEMI patients was 195 (24.5%). Sixty patients
(7.5%) were lost to follow-up: 12 patients died in-hospital,
and 48 patients were lost to follow-up.
3.2. Distribution of the sample according to socio-demographic
variables and history and GRACE variables (Table 1)
Both the STEMI and UA/NSTEMI groups had a similar age
distribution with a mean age of 58 ± 11 years and
57 ± 12 years, respectively. The highest percentage of patients
was in the age group less than 65 years, being 70% for both
groups, and the lowest percentage of patients was in the age
group P74 years, being 7% for the STEMI group and 6%
for the UA/NSTEMI group. The STEMI group had a signiﬁ-
cantly higher rate of male gender (72% versus 64%), smoking
(51% versus 38%), diabetes (45% versus 34%), dyslipidemia
(39% versus 29%) and family history of CAD (16% versus
7%). Interestingly, the percentage of patients who had a previ-
ous history of ischemia in the UA/NSTEMI group was 70%.
This was in the form of STEMI in 26% of patients and UA/
NSTEMI in 44% of patients, compared with only 24%
patients with a history in the STEMI group in the form of
STEMI for 13% of patients and UA/NSTEMI in 11% of
patients (p< 0.001). The UA/NSTEMI group had a higher
rate of hypertension (59% versus 33%), diabetes (45% versus
34%), previous coronary angiography (31% vs 9%), and pre-
vious coronary artery bypass grafting (3% vs 0). Patients with
UA/NSTEMI had a longer duration since the ﬁrst angina pain
until presentation (96 ± 152 h) compared with STEMI
patients (20 ± 32 h; p< 0.0001). On the other hand, STEMI
patients had more warning rest angina pain in the preceding
24 h (5 ± 2) compared with UA/NSTEMI patients (3 ± 2;
p< 0.0001).
Regarding heart rate, both groups had the highest percent-
age of patients in the heart rate group 60–100 bpm (82.2% and
87.4%, respectively). The major portion of the two groups had
a systolic blood pressure P140 mmHg, which was 48.9% in
the STEMI group and 42.9% in the UA/NSTEMI group.
The percentage of patients with elevated creatinine was almost
equal in both groups, being 21.3% in patients with UA/NSTE-
MI versus 21.5% in STEMI patients. The incidence of devel-
oping heart failure was greater in the STEMI group than in
Table 1 Differences between STIMI and UA/NSTEMI groups regarding socio-demographic variables and history of ischemia.
STEMI (NO= 270) UA/NSTEMI (NO= 525) p-Valuea
Male gender 195 (72%) 336 (64%) 0.02
Age in years
<65 189 (70%) 369 (70%) NS
P65<74 63 (23%) 126 (24%)
P74 18 (7%) 30 (6%)
Mean ± SDc 58 ± 11 57 ± 12 NSb
Smoking 138 (51%) 198 (38%) <0.0001
Hypertension 90 (33%) 309 (59%) <0.0001
Diabetes mellitus 93 (34%) 234 (45%) 0.006
Dyslipidemia 78 (29%) 204 (39%) 0.005
Family history of CAD 42 (16%) 39 (7%) <0.0001
Previous CA 24 (9%) 162 (31%) <0.0001
Previous CABG 0 15 (3%) 0.005
History of PAD 6 (2%) 24 (5%) NS
History of ischemia
NO 204 (76%) 156 (30%) <0.0001
STEMI 36 (13%) 135 (26%)
UA/NSTEMI 30 (11%) 234 (44%)
Duration since 1st chest pain (h) 20 ± 32 96 ± 152 <0.0001
Number of rest angina in last 24 h 5 ± 2 3 ± 2 <0.0001
>2 rest angina in last 24 h 225 (83%) 383 (73%) <0.0001
Heart rate (bpm)
<60 12 (4.4%) 9 (1.7%) NS
60–100 222 (82.2%) 459 (87.4%)
>100 36 (13.4%) 57 (10.9%)
Systolic blood pressure (mmHg)
<120 63 (23.3%) 108 (20.6%) NS
120–139 75 (27.8%) 192 (36.6%)
P140 132 (48.9%) 225 (42.9%)
Serum creatinine > 120 mmol/l 58 (21.5%) 112 (21.3%) NS
Killip class
I 228 (84.4%) 468 (89.1%) <0.0001
II 0 (0%) 9 (1.7%)
III 15 (5.6%) 45 (8.6%)
IV 27 (10%) 3 (0.6%)
Cardiac arrest on admission 36 (13.3%) 12 (2.3%) <0.0001
Pulmonary edema on admission 15 (5.6%) 42 (8.0%) NS
Cardiogenic shock on admission 12 (4.4%) 3 (0.6%) <0.0001
ST-segment deviation on admission 270 (100%) 330 (62.9%) <0.0001
Elevated troponin I on admission 207 (95.8%) 147 (50.2%) <0.0001
CA, coronary angiography; CABG, coronary artery bypass grafting; CAD, coronary artery disease; STEMI, ST-elevation myocardial
infarction; PAD, peripheral arterial disease; UA/NSTEMI, unstable angina/Non ST-elevation myocardial infarction.
a Chi-square analysis was used to compare the difference in proportions.
b Independent t-test was used to compare the difference in means.
c SD = Standard deviation.
6 H.M. Abdelmoneim et al.the UA/NSTEMI group, 15.6% and 10.9%, respectively. Car-
diac arrest on admission was signiﬁcantly higher for the
STEMI (36 patients, 13.3%) compared with the UA/NSTEMI
(12 patients, 2.3%). Similarly, cardiogenic shock upon admis-
sion was signiﬁcantly higher with STEMI (12 patients, 4.4%)
compared with UA/NSTEMI (three patients, 0.6%). On the
other hand, pulmonary edema at the presentation had a trend
to be higher with UA/NSTEMI (42 patient, 8.0%) compared
with STEMI (15, 5.6%). However, the difference did not reach
statistical signiﬁcance. Troponin I was positive in 95.8% of
STEMI patients on admission, whereas it was positive in
50.2% of UA/NSTEMI patients. The number of patientswho underwent coronary angiography during their hospital
stay was very low in both groups (1% in STEMI and 5% in
UA/NSTEMI, p< 0.01).
3.3. Distribution of TIMI score factors among patients with
STEMI (Table 2)
There were 21.2% of patients in the STEMI group who had
either diabetes mellitus or hypertension or angina. On the
other hand, a small percentage of patients had a systolic blood
pressure <100 mmHg (11.1%) and heart rate >100 bpm
(30%). Only 15.6% of STEMI patients were complicated by
Table 2 Distribution of the clinical factors used in TIMI score
calculation.





Mean ± SD 57.8 ± 10.7
Diabetes, hypertension or angina 5 (21.2%)
Systolic blood pressure (<100 mmHg) 30 (11.1%)
Heart rate (>100 b/min) 81 (30%)
Killip class of heart failure II–IV 42 (15.6%)
Anterior ST elevation or LBBB 51 (18.8%)
Time to treatment (>4 h) 198 (73.3%)
TIMI for UA/NSTEMI (NO= 525)
Diagnosis (UA or NSTEMI)
UA 330 (62.9%)
NSTEMI 195 (37.1%)
Age (P65 years) 166 (29.7%)
>3 Risk factors for CAD 423 (80.6%)
Known CAD stenosisP 50% 162 (30.9%)
Aspirin use in the past 7 days 369 (70.3%)
>1 episodes rest Angina in <24 h 383 (73%)
ST-segment deviation 330 (62.9%)
Positive cardiac markers 147 (50.2%)
CAD, coronary artery disease; LBBB, left bundle branch block;
NSTEMI, Non ST-elevation myocardial infarction; STEMI,
ST-elevation myocardial infarction; TIMI, Thrombolysis In
Myocardial Infarction; UA, unstable angina.
Validation of TIMI and GRACE scores in ACS patients 7heart failure (Killip classiﬁcation II–IV). Patients who suffered
from anterior STEMI or left bundle branch block represented
the minor component of the STEMI group (18.8%). It is very
important to notice that most of the patients (73.3%) had a
time to treatment of more than 4 h.
3.4. Distribution of TIMI score factors among patients with UA/
NSTEMI (Table 2)
In the patients with UA/NSTEMI, approximately 62.9% were
diagnosed with unstable angina, 29.7% with an ageP65 years,
62.9% with an ST segment changesP0.5 mm, and no evidence
of coronary artery stenosis P50% by previous coronary
angiogram in 69.1%. Most patients (73%) were found to have
had severe anginal episodes. Aspirin was used in the last sevenTable 3 Incidence of in hospital MACE among STEMI and UA/N
STEMI (n= 270)
MACE 63 (23.3%)
In hospital death 12 (4.4%)
Asystole 12 (4.4%)
Cardiogenic shock 6 (2.2%)
Pulmonary edema 15 (5.6%)
Serious arrhythmias 12 (4.4%)
Recurrent non-fatal MI 3 (1.1%)
Recurrent angina 3 (1.1%)
MACE, Major acute cardiac events; NSTEMI, Non ST-elevation myoc
unstable angina.days by 70.3% of the patients, and 80.6% were found to have
>3 risk factors of coronary artery disease.
3.5. In-hospital MACE among STEMI and UA/NSTEMI
groups in patients surviving the admission event (Table 3)
In-hospital MACE was signiﬁcantly higher among the STEMI
patients (23.3%) compared with the UA/NSTEMI (13.7%).
There was a signiﬁcantly higher mortality, asystole, cardio-
genic shock, serious arrhythmia, recurrent non-fatal MI with
STEMI, whereas pulmonary edema displayed a trend toward
being higher in the UA/NSTEMI group (P value did not reach
signiﬁcance).
The GRACE score performance in predicting in-hospital
MACE was signiﬁcantly better compared with TIMI score in
both the STEMI (AUC 0.89 ± 0.03 versus 0.74 ± 0.04, respec-
tively, p 0.0001, Fig. 1A) and UA/NSTEMI patients (AUC
0.90 ± 0.02 versus 0.72 ± 0.03, respectively, p< 0.0001,
Fig. 1D).
3.6. Overall 30-day follow-up results
The overall 30-day follow-up results of patients surviving the
in-hospital course displayed a signiﬁcantly higher incidence
of mortality in the STEMI group (21/243, 9%) compared with
the UA/NSTEMI group (9/492, 2%; p< 0.0001). Recurrent
non-fatal MI was also signiﬁcantly higher in the STEMI group
(84/243, 35%) compared with the UA/NSTEMI group
(75/492, 15%; p< 0.0001).
The mean TIMI score was signiﬁcantly higher in patients
who died during the 30-day follow up, in both the STEMI
group (5.9 ± 1.8) and the UA/NSTEMI group (5.0 ± 0.1)
compared with surviving patients (3.1 ± 1.8 and 3.5 ± 1.1,
respectively, p< 0.0001 for both). Similarly, the mean
GRACE score was signiﬁcantly higher in patients who died
during the 30-day follow-up, in both the STEMI group
(333 ± 47) and the UA/NSTEMI group (284 ± 28) compared
with surviving patients (215 ± 29 and 171 ± 16, respectively,
p< 0.0001 for both). As shown in Fig. 2, it was found that
there is a pattern of an increasing percentage in the observed
30-day mortality rate with increased risk score category for
both the TIMI and GRACE scores in both the STEMI and
UA/NSTEMI groups. The differences in mortality rates for
increasing TIMI and GRACE risk score values were assessed
using the v2 test for trends. The p for the trend value for the
GRACE score was <0.001. The p for trend value for the TIMI
score was signiﬁcant (<0.001).STEMI groups surviving the admission event.









ardial infarction; STEMI, ST-elevation myocardial infarction; UA,
Figure 1 Receiver Operating Characteristic (ROC) curve for the use of both TIMI and GRACE scores in predicting (A) in-hospital
MACE among STEMI patients, (B) 30-day mortality among STEMI patients, (C) 30-day recurrent non-fatal MI among STEMI patients,
(D) in-hospital MACE among UA/NSTEMI patients, (E) 30-day mortality among UA/STEMI patients, (F) 30-day recurrent non-fatal
MI among UA/NSTEMI patients.
8 H.M. Abdelmoneim et al.In STEMI patients, both the GRACE and TIMI scores per-
formed comparably well in predicting both mortality (AUC
0.83 ± 0.06 and 0.86 ± 0.03, respectively, p 0.5, Fig. 1 (B)
and recurrent non-fatal MI (AUC 0.73 ± 0.04 and
0.72 ± 0.03, respectively, p 0.7, Fig. 1 (C), whereas in patients
with UA/NSTEMI, the GRACE score performed signiﬁcantly
better in predicting both mortality with an AUC of
0.97 ± 0.01 compared with 0.89 ± 0.02 for TIMI score
(p< 0.0001; Fig. 1 (E) and recurrent non-fatal MI with an
AUC of 0.85 ± 0.03 compared with 0.75 ± 0.03 for TIMI
score (p 0.0001; Fig. 1 (D).
4. Discussion
4.1. Patient demographics and baseline characteristics
The distribution of ACS patients admitted to our hospital was
34% for STEMI, 24.5% for NSTEMI, and 41.5% for unstable
angina. This distribution is similar to the GRACE registry data
with 32% STEMI, 27% NSTEMI, and 41% UA [18] and the
French registry of ACS (ONACI) with 31% STEMI, 29%
NSTEMI, and 40% UA [19]. Male patients constituted more
than half of our studied sample (66.8%). This was similar to
most of the recent studies supporting that male gender increases
the risk of developing ACS [9,10,18,19]. Our ACS patients are
relatively young with a mean age of approximately 57 years
compared with the Western data with a mean age of approxi-
mately 66 years [9,10,18,19]. There were no signiﬁcant differ-
ences in the baseline clinical characteristics, including the
prevalence of diabetes mellitus, hypertension, dyslipidemia,angina, systolic blood pressure, and aspirin use in the previous
week and initial serum creatinine between the studied sample in
our study and those found in other recent studies [9,10,18,19].
ST-segment deviation at presentation was reported in
62.9% of UA/NSTEMI patients. The reported rates of ST
deviation at presentation varied much in the different reports
being 55.9% [11], 45–47% [20], 32–43% [12], 33.7% [21],
and 26% [10]. There was also a signiﬁcant difference in the
positive cardiac marker percentage at presentation, which
was much greater in our study, reaching 69.5% (95.8% in
STEMI, 50.2% in UA/NSTEMI), than other studies (30–
35%) [9,10,12,21]. This may be due to the delay in patients’
referral to hospitals, as 73.3% of the STEMI patients reached
the hospitals after more than 4 h from the pain onset, which
will give more time to troponin to be detected in the blood.
The resuscitated cardiac arrest on admission was reported to
be 1.2% [9] to 1.5% [21] in all ACS patients compared with
6% in our study (13.3% in STEMI and 2.3% in UA/NSTE-
MI). This difference may also be due to delayed presentation.
The Killip class distribution of our patients at the time of pre-
sentation was comparable to the published data [12,21].
During the calculation of TIMI score of UA/NSTEMI for
patients without prior coronary angiography, we assigned 1
point to that score item if there was a history of myocardial
infarction or coronary revascularization either by PCI or
CABG, in accordance with the suggestion by the authors of
TIMI RS [22]. In patients with UA/NSTEMI, 30.9% were
assigned to have coronary artery stenosis P50% according
to the mentioned recommendation. Our results were different
from those of Maureen Chase et al. [23], where 18% of the
Figure 2 Percentages of observed 30-day mortality (A) by TIMI
score categories among the STEMI group, (B) by TIMI score
categories among the UA/NSTEMI group, and (C) by GRACE
score categories among the total studied sample.
Validation of TIMI and GRACE scores in ACS patients 9patients had coronary artery stenosis based on a previous cor-
onary angiogram. Our results nearly matched those of Yan
et al. due to the application of the same recommendation [10].
4.2. In-hospital outcomes
In this study, STEMI was associated with a higher incidence of
in-hospital MACE, in-hospital mortality, recurrent non-fatal
MI, recovered asystole, cardiogenic shock, and serious
arrhythmia but less incidence of pulmonary edema during
the in-hospital course compared with UA/NSTEMI patients.
At the 30-day follow-up, the STEMI group still had a higher
incidence of all-cause mortality and recurrent non-fatal MI.
These ﬁndings are consistent with those of the GRACE study
[24] and ONACI registry, which reported higher in-hospital
complications and higher mortality in the ﬁrst 24 h in STEMI
patients [19].
In-hospital mortality displayed considerable variation in
different series depending on the sample size, population stud-ied, representation of each ACS entity (UA, NSTEMI, and
STEMI) and also the number of patients who underwent PCI
during the hospital stay, revascularization rate, and technique.
Some studies, such as Granger et al. [21], excluded mortality
cases in the ﬁrst 24 h from some sites, which represented 22%
of the total in-hospital mortality cases. Other studies excluded
patients with a prolonged hospital stay of more than 90 days
[12].
We reported an in-hospital mortality of 4.4% in STEMI
patients and no in-hospital mortality in UA/NSTEMI
patients. A study conducted across Europe in 2000 reported
an in-hospital mortality of 5.9% among patients with acute
MI, 4.3% in patients with MI evolving from UA and 1.6%
in patients with UA [25]. On the other hand, Morrow et al.
found an in-hospital mortality of 12.6% in STEMI patients.
Bradshaw et al. [13] found that the crude in-hospital mortality
among the whole ACS spectrum was 11.0% overall, being
8.9%, 11.1% and 11.5% at small, community and teaching
hospitals, respectively. Patients with STEMI constituted
49.5% of their patients. Of these patients, 59% were treated
with reperfusion therapy, mostly thrombolysis [12]. Granger
et al. reported in-hospital mortality of 4.6% for the whole
ACS sample [21]. Yan et al., concerning patients with
NSTE-ACS, found an in-hospital mortality of 1.8% [10].
4.3. Thirty-day outcomes
We found that patients with STEMI had a higher all-cause
mortality rate (9%) and recurrent non-fatal MI (35%) at
30 days compared with UA/NSTEMI patients (2% and
15%, respectively). Morrow et al., in a large validation study
of TIMI score recruiting 84,029 patients with STEMI,
reported a 30-day mortality of 5.7% [4]. A small single-center
retrospective study of 460 consecutive patients reported a 30-
day all-cause mortality rate of 2.8% and a recurrent non-fatal
MI rate of 5.2% [11].
STEMI was associated with a higher risk of short-term
mortality compared with UA and NSTEMI in the ONACI
registry [19]. Sangu et al. reported that STEMI was an inde-
pendent predictor of re-hospitalization within 30 days after
an ACS [20]. In addition, data from the United Kingdom
indicated that the presence of MI was associated with a higher
30-day mortality rate being 4.5%, 10.4%, and 12.9% in the
UA, NSTEMI, and STEMI groups, respectively [26].
4.4. Evaluation of the risk score models
The GRACE risk score was originally designed to predict
all-cause mortality, and the TIMI risk score was designed to
predict the composite endpoint of death and myocardial
re-infarction. In the current study, both scores were valid in
our patient population and successfully predicted in-hospital
MACE, 30-day all-cause mortality, and 30-day recurrent
non-fatal MI with a good discriminative ability (c-statistics
0.72–0.97) in both STEMI and UA/NSTEMI patients. The
GRACE score displayed a better discriminative ability than
TIMI score in all of these occasions except in STEMI patients.
Both scores performed comparably in predictions of 30-day
mortality and recurrent non-fatal MI.
The discriminative ability of both scores was validated in
numerous reports in different populations [9,10,12–14]. The
10 H.M. Abdelmoneim et al.superiority of the GRACE score was demonstrated in a recently
published large meta-analysis that included all ACS types [27].
In a study from Portugal on patients with UA/NSTEMI,
GRACE performed better than TIMI score in predicting one-
year composite mortality and recurrent MI, whereas at 30 days
the difference was of borderline signiﬁcance [11]. Another small
study from Portugal reported the superiority of the GRACE
score in predicting in-hospital events in ACS patients [28].
Another series from the United States reported that the
GRACE score provided superior discrimination compared
with the TIMI score in predicting in-hospital and 6-month mor-
tality in UA/NSTEMI patients, whereas both scores performed
equally well in STEMI patients [29]. Data from a Canadian reg-
istry of UA/NSTEMI patients indicated that GRACE had a
better discriminative ability in predicting both in-hospital and
one-year mortalities [10]. To our knowledge, only one study
has been performed in Egypt to compare both scores [14]. They
found in 606 patients recruited from three hospitals in Alexan-
dria that GRACE has a better discriminative ability than TIMI
score for the prediction of mortality both in-hospital (in UA/
NSTEMI) and at six months (in both STEMI and UA/NSTE-
MI patients).
A possible explanation for this superiority of GRACE is
that it was developed from a community-based cohort,
whereas TIMI score was developed from data collected from
clinical trials. There are some characteristics in each trial that
can make the population within the trials different from others
and from the community, which may not be adequately mea-
sured. This can result in the trial-based population result not
being entirely generalizable to the community [30]. Granger
et al. summarized the advantages of the GRACE model over
TIMI score in terms of three main differences. First, it is the
ﬁrst mortality model to span the entire spectrum of ACS. This
advantage is important because ACS patients are not only dif-
ﬁcult to categorize at the time of presentation as having MI or
unstable angina but also may have varying amounts of
dynamic ST-segment shift and may rapidly progress from
one category to another. Second, it is based on a relatively
unselected patient population, representing those observed in
general practice (community based). Third, it incorporates
new variables that add considerable predictive information,
such as serum creatinine [21].
The advantage of TIMI risk score is that it is based on clin-
ical information, rendering it suitable for bedside early risk
stratiﬁcation with no need for a computer. Patients with
ACS are in unstable condition, necessitating continuous risk
stratiﬁcation throughout the entire hospital admission period,
which makes TIMI score more feasible for use by physicians
[13].
Study limitations: Details on management data could not be
collected and hence analysis of the effect of management strat-
egy on the outcome was not done. This is considered a limita-
tion of this study.5. Conclusion
ACS occurs at a relatively young age in our locality, in patients
sharing the common known risk factors of CAD. STEMI
patients, in our locality, represent approximately one-third of
ACS patients and are associated with worse in-hospital as well
as 30-day outcomes. Both TIMI and GRACE risk scores arevalid for use for ACS patients in the Assiut governorate, with
a better discriminative ability for the GRACE score, especially
in UA/STEMI patients.
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